Q-omics provides the consensus-scored RBM5 profile across patient tissues and cancer cell-line models. RBM5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RBM5 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, RBM5 RNA expression shows 21,328 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, LIHC, and UVM as cancer lineages where RBM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM5 survival associations across molecular data types. RBM5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM5 RNA expression–survival associations across cancer types. High RBM5 expression shows unfavorable associations in ACC, KICH, KIRC and LIHC, but favorable associations in SCLC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RBM5 RNA expression.
This table summarizes RBM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RBM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM5 shows lower tumor expression in KICH, LUSC, BRCA and UCEC and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher RBM5 RNA expression in tumor versus normal tissue (log2 FC = +0.766, t-test p < 0.001).
This table shows molecular features associated with RBM5 in patient tissues and cancer cell lines. In patient samples, RBM5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
